(2R)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide

Formula:C22H43N5O13 Mutagenic:none Tumorigenic:none Reproductive Effective:none (2R)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide is not a drug-like molecule.

MolName(2R)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide
MolecularFormulaC22H43N5O13
SmilesNCC[C@H](C(N[C@H](C[C@@H]([C@H]([C@@H]1O)O[C@H]([C@@H]([C@H]2O)O)O[C@H](CN)[C@H]2O)N)[C@@H]1O[C@H](C([C@H]1N)O)O[C@H](CO)[C@H]1O)=O)O
InChIInChI=1S/C22H43N5O13/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36)/t6-,7-,8-,9-,10-,11-,12+,13+,14?,15-,16-,17+,18+,19+,21-,22-/m1/s1
InChIKLKCWBDHBTVXHDL-WOHQNDRNSA-N
TotalMolweight585.605
Molweight585.605
MonoisotopicMass585.28574
CLogP-8.5032
CLogS0.233
H Acceptors18
H Donors13
TotalSurfaceArea395.89
Relative PSA0.58193
PolarSurfaceArea331.94
Druglikeness5.3041
Mutagenicnone
Tumorigenicnone
Reproductive Effectivenone
Irritantnone
Nasty Functions
Shape Index0.4
Fragments1
Non HAtoms40
NonCHAtoms18
Electronegative Atoms18
StereoCenters16
Rotatable Bond10
Rings Closures3
Small Rings3
Sp3Atoms37
Amides1
Amines4
AlkylAmines4
BasicNitrogens4
StereoConunknown chirality

Request More Details | (2R)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide


SKU Product Name Product Unit Qty Supplier Email
User Name
User Email
Additional Comments